Naveen Pemmaraju, MD, discusses results from a phase I/II trial of tagraxofusp in patients with relapsed/refractory myelofibrosis, a disease with only one approved treatment option.
Recent Articles
NIH Awards $1.5 Million for Fingerstick Hemophilia Test
The NIH has awarded $1.5 million to continue development of rHEALTH LLC’s fingerstick blood test for monitoring FVIII and emicizumab levels in hemophilia. The...
Current Issue
October 2020 Volume 6, Issue 12
This issue examines racism in the U.S. health care system, discusses the FDA's newly loosened blood donation restrictions, and more.